Traders should monitor the 1H2026 NDA submission and 3Q2026 CHAPTER-3 topline data as primary catalysts; current financials are secondary. Cash runway appears sufficient for now, but future dilution risk increases if commercialization is delayed or approval denied.
PHVS drugs
PHVS drug pipeline →How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Apr 2 $28.56entry
- T+1 · 8mo ago −0.67%α −1.14% · $28.37
- T+5 · 7mo ago −6.76%α −10.38% · $26.63
- T+20 · 7mo ago +8.58%α −1.30% · $31.01
- T+60 · 5mo ago +21.08%α +6.92% · $34.58
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Pharvaris reported a narrow EPS beat of 3% ($-0.60 vs $-0.62 consensus) with no revenue, typical for a pre-revenue biotech. The focus remains on upcoming catalysts: NDA submission for deucrictibant IR in 1H2026 and topline data from the CHAPTER-3 pivotal trial in 3Q2026. Cash runway of €292M supports operations through key inflection points.
Key Financial Metrics
Key Facts
- EPS of $-0.60 vs. consensus of $-0.62 (3% beat), revenue $0 in line with expectations
- Cash and cash equivalents: €292 million as of December 31, 2025
- NDA submission for deucrictibant IR (on-demand HAE treatment) on track for 1H2026
- Topline data from CHAPTER-3 trial (prophylactic HAE treatment) expected in 3Q2026
- Enrollment ongoing in CREAATE trial for AAE-C1INH, a potential expansion indication
Financial Impact
Minimal near-term financial impact; company remains pre-revenue with expected losses continuing into 2026
Risk Factors
- Regulatory risk around NDA approval for deucrictibant IR in 2026
- Clinical risk in CHAPTER-3 and CREAATE trials failing to replicate RAPIDe-3 success
- Dilution risk if additional funding is needed beyond 2026
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3267207 |
Track record
51 reports on PHVS
15 of 18 bullish or bearish reports moved the stock their way by T+5. Best: +23.73% at T+20 after the Sep 17, 2026 report. 17 of 19 went positive at some point.
Filters
- Nov 16, 2026today SC 13G Neutral 4/10 Entry $33.19 Now $32.44 −2.26% settles Nov 23
- Nov 13, 20263d ago SC 13G/A Bearish 5/10 Entry $33.59 Now $32.44 +3.42% settles Nov 23
- Nov 12, 20264d ago Press Release Bullish 7/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Nov 12, 20264d ago 6-K Neutral 4/10 No price data
- Nov 12, 20264d ago Press Release Neutral 5/10 Entry $33.83 Now $32.44 −4.11% settles Nov 19
- Sep 25, 20267w ago Insider Cluster Bearish 6/10 Entry $32.02 to $31.19 Now $32.44 −1.31% ▲ +2.59% +2.37% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 7/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 24, 20267w ago Insider Cluster Bearish 5/10 Entry $32.99 to $31.01 Now $32.44 +1.67% ▲ +6.00% +5.59% vs SPY
- Sep 23, 20267w ago Insider Cluster Bearish 6/10 Entry $33.07 to $31.72 Now $32.44 +1.91% ▲ +4.08% +3.41% vs SPY
- Sep 21, 20268w ago Insider Cluster Bearish 5/10 Entry $36.02 to $31.91 Now $32.44 +9.94% ▲ +11.41% +10.39% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers